http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Jul 2026 07:45:21 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Intensity+Therapeutics+resumes+breast+cancer+trial+in+Switzerland/26770968.html <p>Intensity Therapeutics, Inc. (Nasdaq: INTS) announced July 15 that it has resumed patient dosing in its INVINCIBLE-4 Study, a Phase 2 clinical trial evaluating its drug candidate INT230-6 in patients with early-stage, operable triple-negative breast cancer.</p> <p>The trial, identified as NCT06358573, had been paused to evaluate skin irritation observed in some patients. In March 2026, the company submitted a protocol amendment to Swissmedic and the Swiss Ethics Committee to resume enrollment using a lower drug-to-tumor volume ratio and a single injection of INT230-6. New patients have since been dosed in Switzerland.</p> <p>The study uses a two-cohort design. One cohort receives a single http://www.streetinsider.com/FDA/Intensity+Therapeutics+resumes+breast+cancer+trial+in+Switzerland/26770968.html Wed, 15 Jul 2026 07:45:21 -0400 A.60012012 INTS O.22227537 O.49209974 http://www.streetinsider.com/FDA/Intensity+Therapeutics+resumes+breast+cancer+trial+in+Switzerland/26770968.html <p>Intensity Therapeutics, Inc. (Nasdaq: INTS) announced July 15 that it has resumed patient dosing in its INVINCIBLE-4 Study, a Phase 2 clinical trial evaluating its drug candidate INT230-6 in patients with early-stage, operable triple-negative breast cancer.</p> <p>The trial, identified as NCT06358573, had been paused to evaluate skin irritation observed in some patients. In March 2026, the company submitted a protocol amendment to Swissmedic and the Swiss Ethics Committee to resume enrollment using a lower drug-to-tumor volume ratio and a single injection of INT230-6. New patients have since been dosed in Switzerland.</p> <p>The study uses a two-cohort design. One cohort receives a single http://www.streetinsider.com/FDA/Intensity+Therapeutics+resumes+breast+cancer+trial+in+Switzerland/26770968.html Wed, 15 Jul 2026 07:45:21 -0400 A.60012012 INTS O.22227537 O.49209974 http://www.streetinsider.com/FDA/Intensity+Therapeutics+resumes+breast+cancer+trial+in+Switzerland/26770968.html <p>Intensity Therapeutics, Inc. (Nasdaq: INTS) announced July 15 that it has resumed patient dosing in its INVINCIBLE-4 Study, a Phase 2 clinical trial evaluating its drug candidate INT230-6 in patients with early-stage, operable triple-negative breast cancer.</p> <p>The trial, identified as NCT06358573, had been paused to evaluate skin irritation observed in some patients. In March 2026, the company submitted a protocol amendment to Swissmedic and the Swiss Ethics Committee to resume enrollment using a lower drug-to-tumor volume ratio and a single injection of INT230-6. New patients have since been dosed in Switzerland.</p> <p>The study uses a two-cohort design. One cohort receives a single http://www.streetinsider.com/FDA/Intensity+Therapeutics+resumes+breast+cancer+trial+in+Switzerland/26770968.html Wed, 15 Jul 2026 07:45:21 -0400 A.60012012 INTS O.22227537 O.49209974 http://www.streetinsider.com/FDA/Intensity+Therapeutics+resumes+breast+cancer+trial+in+Switzerland/26770968.html <p>Intensity Therapeutics, Inc. (Nasdaq: INTS) announced July 15 that it has resumed patient dosing in its INVINCIBLE-4 Study, a Phase 2 clinical trial evaluating its drug candidate INT230-6 in patients with early-stage, operable triple-negative breast cancer.</p> <p>The trial, identified as NCT06358573, had been paused to evaluate skin irritation observed in some patients. In March 2026, the company submitted a protocol amendment to Swissmedic and the Swiss Ethics Committee to resume enrollment using a lower drug-to-tumor volume ratio and a single injection of INT230-6. New patients have since been dosed in Switzerland.</p> <p>The study uses a two-cohort design. One cohort receives a single http://www.streetinsider.com/FDA/Intensity+Therapeutics+resumes+breast+cancer+trial+in+Switzerland/26770968.html Wed, 15 Jul 2026 07:45:21 -0400 A.60012012 INTS O.22227537 O.49209974 http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html <div class="xn-content"> <p class="prntac">First patients dosed in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></p><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=2899699664&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fintensitytherapeutics.com%2F___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6MzMzOToxNTlhZjk3MGY3YTRkMTNmODA0MzY2ZWMxNzM0ZjVhOWI1NmVkNWE5Y2RjODAxNWI3NjE5Yjk0N2VlOGQ5MzM4OnA6VDpG&amp;a=Intensity+Therapeutics%2C+Inc" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc</span></a>. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>. The trial (<a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=3820774963&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT06358573%3Fterm%3DINT230-6%26rank%3D4___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6N2Q3Mjo2Yjk3MDU3NjBhMGI5ODRlN2ExMjdhNTJiMzIyY2RlMWM2OThiYjY4NjhhZTA1ZTc1Y2UwNjUxYjVmYzBkZDlmOnA6VDpG&amp;a=NCT06358573" target="_blank" rel="nofollow">NCT06358573</a>) analyzes INT230-6 given before http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html Wed, 15 Jul 2026 07:45:00 -0400 A.60012012 INTS O.22227537 O.49209974 http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html <div class="xn-content"> <p class="prntac">First patients dosed in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></p><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=2899699664&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fintensitytherapeutics.com%2F___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6MzMzOToxNTlhZjk3MGY3YTRkMTNmODA0MzY2ZWMxNzM0ZjVhOWI1NmVkNWE5Y2RjODAxNWI3NjE5Yjk0N2VlOGQ5MzM4OnA6VDpG&amp;a=Intensity+Therapeutics%2C+Inc" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc</span></a>. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>. The trial (<a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=3820774963&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT06358573%3Fterm%3DINT230-6%26rank%3D4___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6N2Q3Mjo2Yjk3MDU3NjBhMGI5ODRlN2ExMjdhNTJiMzIyY2RlMWM2OThiYjY4NjhhZTA1ZTc1Y2UwNjUxYjVmYzBkZDlmOnA6VDpG&amp;a=NCT06358573" target="_blank" rel="nofollow">NCT06358573</a>) analyzes INT230-6 given before http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html Wed, 15 Jul 2026 07:45:00 -0400 A.60012012 INTS O.22227537 O.49209974 http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html <div class="xn-content"> <p class="prntac">First patients dosed in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></p><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=2899699664&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fintensitytherapeutics.com%2F___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6MzMzOToxNTlhZjk3MGY3YTRkMTNmODA0MzY2ZWMxNzM0ZjVhOWI1NmVkNWE5Y2RjODAxNWI3NjE5Yjk0N2VlOGQ5MzM4OnA6VDpG&amp;a=Intensity+Therapeutics%2C+Inc" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc</span></a>. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>. The trial (<a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=3820774963&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT06358573%3Fterm%3DINT230-6%26rank%3D4___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6N2Q3Mjo2Yjk3MDU3NjBhMGI5ODRlN2ExMjdhNTJiMzIyY2RlMWM2OThiYjY4NjhhZTA1ZTc1Y2UwNjUxYjVmYzBkZDlmOnA6VDpG&amp;a=NCT06358573" target="_blank" rel="nofollow">NCT06358573</a>) analyzes INT230-6 given before http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html Wed, 15 Jul 2026 07:45:00 -0400 A.60012012 INTS O.22227537 O.49209974 http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html <div class="xn-content"> <p class="prntac">First patients dosed in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></p><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=2899699664&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fintensitytherapeutics.com%2F___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6MzMzOToxNTlhZjk3MGY3YTRkMTNmODA0MzY2ZWMxNzM0ZjVhOWI1NmVkNWE5Y2RjODAxNWI3NjE5Yjk0N2VlOGQ5MzM4OnA6VDpG&amp;a=Intensity+Therapeutics%2C+Inc" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc</span></a>. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>. The trial (<a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=3820774963&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT06358573%3Fterm%3DINT230-6%26rank%3D4___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6N2Q3Mjo2Yjk3MDU3NjBhMGI5ODRlN2ExMjdhNTJiMzIyY2RlMWM2OThiYjY4NjhhZTA1ZTc1Y2UwNjUxYjVmYzBkZDlmOnA6VDpG&amp;a=NCT06358573" target="_blank" rel="nofollow">NCT06358573</a>) analyzes INT230-6 given before http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html Wed, 15 Jul 2026 07:45:00 -0400 A.60012012 INTS O.22227537 O.49209974 http://www.streetinsider.com/PRNewswire/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html <div class="xn-content"> <p class="prntac">First patients dosed in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></p><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=2899699664&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fintensitytherapeutics.com%2F___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6MzMzOToxNTlhZjk3MGY3YTRkMTNmODA0MzY2ZWMxNzM0ZjVhOWI1NmVkNWE5Y2RjODAxNWI3NjE5Yjk0N2VlOGQ5MzM4OnA6VDpG&amp;a=Intensity+Therapeutics%2C+Inc" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc</span></a>. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>. The trial (<a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=3820774963&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT06358573%3Fterm%3DINT230-6%26rank%3D4___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6N2Q3Mjo2Yjk3MDU3NjBhMGI5ODRlN2ExMjdhNTJiMzIyY2RlMWM2OThiYjY4NjhhZTA1ZTc1Y2UwNjUxYjVmYzBkZDlmOnA6VDpG&amp;a=NCT06358573" target="_blank" rel="nofollow">NCT06358573</a>) analyzes INT230-6 given before http://www.streetinsider.com/PRNewswire/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html Wed, 15 Jul 2026 07:45:00 -0400 A.60012012 INTS O.22227537 O.49209974 http://www.streetinsider.com/PRNewswire/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html <div class="xn-content"> <p class="prntac">First patients dosed in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></p><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=2899699664&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fintensitytherapeutics.com%2F___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6MzMzOToxNTlhZjk3MGY3YTRkMTNmODA0MzY2ZWMxNzM0ZjVhOWI1NmVkNWE5Y2RjODAxNWI3NjE5Yjk0N2VlOGQ5MzM4OnA6VDpG&amp;a=Intensity+Therapeutics%2C+Inc" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc</span></a>. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>. The trial (<a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=3820774963&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT06358573%3Fterm%3DINT230-6%26rank%3D4___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6N2Q3Mjo2Yjk3MDU3NjBhMGI5ODRlN2ExMjdhNTJiMzIyY2RlMWM2OThiYjY4NjhhZTA1ZTc1Y2UwNjUxYjVmYzBkZDlmOnA6VDpG&amp;a=NCT06358573" target="_blank" rel="nofollow">NCT06358573</a>) analyzes INT230-6 given before http://www.streetinsider.com/PRNewswire/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html Wed, 15 Jul 2026 07:45:00 -0400 A.60012012 INTS O.22227537 O.49209974 http://www.streetinsider.com/PRNewswire/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html <div class="xn-content"> <p class="prntac">First patients dosed in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></p><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=2899699664&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fintensitytherapeutics.com%2F___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6MzMzOToxNTlhZjk3MGY3YTRkMTNmODA0MzY2ZWMxNzM0ZjVhOWI1NmVkNWE5Y2RjODAxNWI3NjE5Yjk0N2VlOGQ5MzM4OnA6VDpG&amp;a=Intensity+Therapeutics%2C+Inc" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc</span></a>. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>. The trial (<a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=3820774963&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT06358573%3Fterm%3DINT230-6%26rank%3D4___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6N2Q3Mjo2Yjk3MDU3NjBhMGI5ODRlN2ExMjdhNTJiMzIyY2RlMWM2OThiYjY4NjhhZTA1ZTc1Y2UwNjUxYjVmYzBkZDlmOnA6VDpG&amp;a=NCT06358573" target="_blank" rel="nofollow">NCT06358573</a>) analyzes INT230-6 given before http://www.streetinsider.com/PRNewswire/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html Wed, 15 Jul 2026 07:45:00 -0400 A.60012012 INTS O.22227537 O.49209974 http://www.streetinsider.com/PRNewswire/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html <div class="xn-content"> <p class="prntac">First patients dosed in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location></p><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=2899699664&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fintensitytherapeutics.com%2F___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6MzMzOToxNTlhZjk3MGY3YTRkMTNmODA0MzY2ZWMxNzM0ZjVhOWI1NmVkNWE5Y2RjODAxNWI3NjE5Yjk0N2VlOGQ5MzM4OnA6VDpG&amp;a=Intensity+Therapeutics%2C+Inc" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc</span></a>. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>. The trial (<a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4731510-1&amp;h=3820774963&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr02%2F___https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT06358573%3Fterm%3DINT230-6%26rank%3D4___.YzJlOmhvY2hwcm9kOmM6b2ZmaWNlMzY1X2VtYWlsc19hdHRhY2htZW50OjQ2OGE2NjU4ZThhNWY3NDYzY2M0Mzk0NmQ5YWM2MjNiOjc6N2Q3Mjo2Yjk3MDU3NjBhMGI5ODRlN2ExMjdhNTJiMzIyY2RlMWM2OThiYjY4NjhhZTA1ZTc1Y2UwNjUxYjVmYzBkZDlmOnA6VDpG&amp;a=NCT06358573" target="_blank" rel="nofollow">NCT06358573</a>) analyzes INT230-6 given before http://www.streetinsider.com/PRNewswire/Intensity+Therapeutics%2C+Inc.+Restarts+Patient+Treatment+in+the+Randomized%2C+Presurgical+Triple+Negative+Breast+Cancer+Phase+2+Clinical+Trial+%28INVINCIBLE-4+Study%29/26770964.html Wed, 15 Jul 2026 07:45:00 -0400 A.60012012 INTS O.22227537 O.49209974 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++INTENSITY+THERAPEUTICS%2C++++++++++++++/26747468.html si-local-file:///var/storage/secattach/20260708/26747468.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++INTENSITY+THERAPEUTICS%2C++++++++++++++/26747468.html Wed, 08 Jul 2026 16:01:00 -0400 INTS O.22227537 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++INTENSITY+THERAPEUTICS%2C++++++++++++++/26747468.html si-local-file:///var/storage/secattach/20260708/26747468.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++INTENSITY+THERAPEUTICS%2C++++++++++++++/26747468.html Wed, 08 Jul 2026 16:01:00 -0400 INTS O.22227537 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INTENSITY+THERAPEUTICS%2C+++For%3A+Jun+30++Filed+by%3A+Wesolowski+John+M/26720700.html si-local-file:///var/storage/secattach/20260701/26720700.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INTENSITY+THERAPEUTICS%2C+++For%3A+Jun+30++Filed+by%3A+Wesolowski+John+M/26720700.html Wed, 01 Jul 2026 16:09:00 -0400 INTS O.22227537 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INTENSITY+THERAPEUTICS%2C+++For%3A+Jun+30++Filed+by%3A+Wesolowski+John+M/26720700.html si-local-file:///var/storage/secattach/20260701/26720700.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INTENSITY+THERAPEUTICS%2C+++For%3A+Jun+30++Filed+by%3A+Wesolowski+John+M/26720700.html Wed, 01 Jul 2026 16:09:00 -0400 INTS O.22227537 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INTENSITY+THERAPEUTICS%2C+++For%3A+Jun+30++Filed+by%3A+Talamo+Joseph/26720674.html si-local-file:///var/storage/secattach/20260701/26720674.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INTENSITY+THERAPEUTICS%2C+++For%3A+Jun+30++Filed+by%3A+Talamo+Joseph/26720674.html Wed, 01 Jul 2026 16:08:00 -0400 INTS O.22227537 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INTENSITY+THERAPEUTICS%2C+++For%3A+Jun+30++Filed+by%3A+Talamo+Joseph/26720674.html si-local-file:///var/storage/secattach/20260701/26720674.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++INTENSITY+THERAPEUTICS%2C+++For%3A+Jun+30++Filed+by%3A+Talamo+Joseph/26720674.html Wed, 01 Jul 2026 16:08:00 -0400 INTS O.22227537 http://www.streetinsider.com/Corporate+News/Intensity+Therapeutics+resumes+clinical+trials%2C+pursues+partners+for+INT230-6/26717151.html <p>Intensity Therapeutics, Inc. (Nasdaq: INTS) issued a mid-year update on July 1, 2026, outlining progress across its INT230-6 clinical programs, partnering activity, and balance sheet position.</p><p>The company resumed enrollment in its Phase 3 INVINCIBLE-3 study in soft tissue sarcoma at a limited number of U.S. sites in April 2026, after pausing new enrollments in March 2025 due to funding constraints. The study compares INT230-6 as a monotherapy against standard-of-care drugs in second- and third-line treatment, with overall survival as the primary endpoint.</p><p>In presurgical triple-negative breast cancer, the Phase 2 INVINCIBLE-4 study received full approval to resume enrollment from Swissmedic and http://www.streetinsider.com/Corporate+News/Intensity+Therapeutics+resumes+clinical+trials%2C+pursues+partners+for+INT230-6/26717151.html Wed, 01 Jul 2026 08:01:23 -0400 INTS http://www.streetinsider.com/FDA/Intensity+Therapeutics+resumes+clinical+trials%2C+pursues+partners+for+INT230-6/26717151.html <p>Intensity Therapeutics, Inc. (Nasdaq: INTS) issued a mid-year update on July 1, 2026, outlining progress across its INT230-6 clinical programs, partnering activity, and balance sheet position.</p><p>The company resumed enrollment in its Phase 3 INVINCIBLE-3 study in soft tissue sarcoma at a limited number of U.S. sites in April 2026, after pausing new enrollments in March 2025 due to funding constraints. The study compares INT230-6 as a monotherapy against standard-of-care drugs in second- and third-line treatment, with overall survival as the primary endpoint.</p><p>In presurgical triple-negative breast cancer, the Phase 2 INVINCIBLE-4 study received full approval to resume enrollment from Swissmedic and http://www.streetinsider.com/FDA/Intensity+Therapeutics+resumes+clinical+trials%2C+pursues+partners+for+INT230-6/26717151.html Wed, 01 Jul 2026 08:01:23 -0400 INTS http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics+Provides+Mid-Year+Update+Highlighting+Late-Stage+Development+Programs+and+Strategic+Partnering+Opportunities+for+INT230-6/26717055.html <div class="xn-content"> <ul type="disc"><li><i>Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer<br /><br /></i></li><li><i>Over 200 patients enrolled in completed INT230-6 studies with a peer-reviewed paper published<br /><br /></i></li><li><i>Active strategic partnering initiatives supported by maturing INT230-6 clinical and regulatory profile<br /><br /></i></li><li><i>Strengthened balance sheet supporting disciplined clinical development strategy</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc.</span> ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics+Provides+Mid-Year+Update+Highlighting+Late-Stage+Development+Programs+and+Strategic+Partnering+Opportunities+for+INT230-6/26717055.html Wed, 01 Jul 2026 08:00:00 -0400 A.60012012 INTS O.01654910 O.22227537 http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics+Provides+Mid-Year+Update+Highlighting+Late-Stage+Development+Programs+and+Strategic+Partnering+Opportunities+for+INT230-6/26717055.html <div class="xn-content"> <ul type="disc"><li><i>Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer<br /><br /></i></li><li><i>Over 200 patients enrolled in completed INT230-6 studies with a peer-reviewed paper published<br /><br /></i></li><li><i>Active strategic partnering initiatives supported by maturing INT230-6 clinical and regulatory profile<br /><br /></i></li><li><i>Strengthened balance sheet supporting disciplined clinical development strategy</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc.</span> ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics+Provides+Mid-Year+Update+Highlighting+Late-Stage+Development+Programs+and+Strategic+Partnering+Opportunities+for+INT230-6/26717055.html Wed, 01 Jul 2026 08:00:00 -0400 A.60012012 INTS O.01654910 O.22227537 http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics+Provides+Mid-Year+Update+Highlighting+Late-Stage+Development+Programs+and+Strategic+Partnering+Opportunities+for+INT230-6/26717055.html <div class="xn-content"> <ul type="disc"><li><i>Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer<br /><br /></i></li><li><i>Over 200 patients enrolled in completed INT230-6 studies with a peer-reviewed paper published<br /><br /></i></li><li><i>Active strategic partnering initiatives supported by maturing INT230-6 clinical and regulatory profile<br /><br /></i></li><li><i>Strengthened balance sheet supporting disciplined clinical development strategy</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc.</span> ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics+Provides+Mid-Year+Update+Highlighting+Late-Stage+Development+Programs+and+Strategic+Partnering+Opportunities+for+INT230-6/26717055.html Wed, 01 Jul 2026 08:00:00 -0400 A.60012012 INTS O.01654910 O.22227537 http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics+Provides+Mid-Year+Update+Highlighting+Late-Stage+Development+Programs+and+Strategic+Partnering+Opportunities+for+INT230-6/26717055.html <div class="xn-content"> <ul type="disc"><li><i>Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer<br /><br /></i></li><li><i>Over 200 patients enrolled in completed INT230-6 studies with a peer-reviewed paper published<br /><br /></i></li><li><i>Active strategic partnering initiatives supported by maturing INT230-6 clinical and regulatory profile<br /><br /></i></li><li><i>Strengthened balance sheet supporting disciplined clinical development strategy</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc.</span> ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system http://www.streetinsider.com/Press+Releases/Intensity+Therapeutics+Provides+Mid-Year+Update+Highlighting+Late-Stage+Development+Programs+and+Strategic+Partnering+Opportunities+for+INT230-6/26717055.html Wed, 01 Jul 2026 08:00:00 -0400 A.60012012 INTS O.01654910 O.22227537 http://www.streetinsider.com/PRNewswire/Intensity+Therapeutics+Provides+Mid-Year+Update+Highlighting+Late-Stage+Development+Programs+and+Strategic+Partnering+Opportunities+for+INT230-6/26717055.html <div class="xn-content"> <ul type="disc"><li><i>Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer<br /><br /></i></li><li><i>Over 200 patients enrolled in completed INT230-6 studies with a peer-reviewed paper published<br /><br /></i></li><li><i>Active strategic partnering initiatives supported by maturing INT230-6 clinical and regulatory profile<br /><br /></i></li><li><i>Strengthened balance sheet supporting disciplined clinical development strategy</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ct.sheton" idsrc="xmltag.org" >SHELTON, Conn.</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INTS" idsrc="xmltag.org" >Intensity Therapeutics, Inc.</span> ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system http://www.streetinsider.com/PRNewswire/Intensity+Therapeutics+Provides+Mid-Year+Update+Highlighting+Late-Stage+Development+Programs+and+Strategic+Partnering+Opportunities+for+INT230-6/26717055.html Wed, 01 Jul 2026 08:00:00 -0400 A.60012012 INTS O.01654910 O.22227537